Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imfinzi (durvalumab)
Pharma
AZ faces FDA challenge as Imfinzi-Lynparza miss survival goal
At the final analysis of the Duo-O trial, Imfinzi and Lynparza failed to mount a survival benefit in first-line non-BRCA-mutated ovarian cancer.
Angus Liuu
Oct 19, 2025 4:15am
Keytruda, Padcev cut risk of death by 50% in MIBC patient subset
Oct 18, 2025 10:30am
AZ's Imfinzi looks set up for another bladder cancer expansion
Oct 17, 2025 8:10am
AZ, Daiichi's Datroway scores overall survival win in TNBC
Oct 6, 2025 10:48am
AZ, Genentech, Merck top oncology HCP promotions: report
Aug 14, 2025 11:52am
ASCO: AZ looks to bring immunotherapy to early stomach cancer
Jun 1, 2025 8:00am
